Resveratrol improves hepatic steatosis by inducing autophagy through the cAMP signaling pathway

Molecular Nutrition and Food Research

Volumn 59, Issue 8, 2015, Pages 1443-1457

  Zhang, Yong ^a   Chen, Ming liang ^a   Zhou, Yong ^a   Yi, Long ^a   Gao, Yan xiang ^a   Ran, Li ^a   Chen, Shi hui ^a   Zhang, Ting ^a   Zhou, Xi ^a   Zou, Dan ^a   Wu, Bin ^a   Wu, Ying ^a   Chang, Hui ^a   Zhu, Jun dong ^a   Zhang, Qian yong ^a   Mi, Man tian ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Hepatocyte; NAFLD; Resveratrol; SIRT1; Treatment

Indexed keywords

MUS; RICE STRIPE VIRUS;

ADENYLATE CYCLASE; ANTIOXIDANT; CYCLIC AMP; ENZYME INHIBITOR; FATTY ACID; RESVERATROL; SIRT1 PROTEIN, MOUSE; SIRTUIN 1; STILBENE DERIVATIVE;

129 MOUSE; AGONISTS; ANIMAL; ANTAGONISTS AND INHIBITORS; AUTOPHAGY; CHEMISTRY; DIET THERAPY; DIETARY SUPPLEMENT; DRUG EFFECTS; ENZYME INDUCTION; GENETICS; HEPG2 CELL LINE; HUMAN; LIPID METABOLISM; LIVER; METABOLISM; NONALCOHOLIC FATTY LIVER; PATHOLOGY; RNA INTERFERENCE; SECOND MESSENGER; TRANSMISSION ELECTRON MICROSCOPY; ULTRASTRUCTURE;

ADENYLYL CYCLASES; ANIMALS; ANTIOXIDANTS; AUTOPHAGY; CYCLIC AMP; DIETARY SUPPLEMENTS; ENZYME INDUCTION; ENZYME INHIBITORS; FATTY ACIDS, NONESTERIFIED; HEP G2 CELLS; HUMANS; LIPID METABOLISM; LIVER; MICE, 129 STRAIN; MICROSCOPY, ELECTRON, TRANSMISSION; NON-ALCOHOLIC FATTY LIVER DISEASE; RNA INTERFERENCE; SECOND MESSENGER SYSTEMS; SIRTUIN 1; STILBENES;

EID: 84938553069     PISSN: 16134125     EISSN: 16134133     Source Type: Journal    
DOI: 10.1002/mnfr.201500016     Document Type: Article

References (59)

1. Farrell, G. C., Larter, C. Z., Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 2006, 43, S99-S112.
2. McCullough, A. J., Pathophysiology of nonalcoholic steatohepatitis. J. Clin. Gastroenterol. 2006, 40 (Suppl1), S17-S29.
3. Ibrahim, M. A., Kelleni, M., Geddawy, A., Nonalcoholic fatty liver disease: current and potential therapies. Life Sci. 2013, 92, 114-118.
4. deWit, N. J., Afman, L. A., Mensink, M., Muller, M., Phenotyping the effect of diet on non-alcoholic fatty liver disease. J. Hepatol. 2012, 57, 1370-1373.
5. McCarthy, E. M., Rinella, M. E., The role of diet and nutrient composition in nonalcoholic Fatty liver disease. J. Acad. Nutr. Diet. 2012, 112, 401-409.
6. Bujanda, L., Hijona, E., Larzabal, M., Beraza, M. et al., Resveratrol inhibits nonalcoholic fatty liver disease in rats. BMC Gastroenterol. 2008, 8, 40.
7. Wang, G. L., Fu, Y. C., Xu, W. C., Feng, Y. Q. et al., Resveratrol inhibits the expression of SREBP1 in cell model of steatosis via Sirt1-FOXO1 signaling pathway. Biochem. Biophys. Res. Commun. 2009, 380, 644-649.
8. Czaja, M. J., Functions of autophagy in hepatic and pancreatic physiology and disease. Gastroenterology 2011, 140, 1895-1908.
9. He, Z., Liu, H., Agostini, M., Yousefi, S. et al., p73 regulates autophagy and hepatocellular lipid metabolism through a transcriptional activation of the ATG5 gene. Cell Death Differ. 2013, 20, 1415-1424.
10. Heaton, N. S., Randall, G., Dengue virus-induced autophagy regulates lipid metabolism. Cell Host Microbe 2010, 8, 422-432.
11. Codogno, P., Meijer, A. J., Autophagy: a potential link between obesity and insulin resistance. Cell Metab. 2010, 11, 449-451.
12. Liu, H. Y., Han, J. M., Cao, S. Y., Hong, T. et al., Hepatic Autophagy is suppressed in the presence of insulin resistance and hyperinsulinemia inhibition of FoxO1-dependent expression of key autophagy genes by insulin. J. Biol. Chem. 2009, 284, 31484-31492.
13. Opipari, A. W., Tan, L. J., Boitano, A. E., Sorenson, D. R. et al., Resveratrol-induced autophagocytosis in ovarian cancer cells. Cancer Res. 2004, 64, 696-703.
14. Chen, M. L., Yi, L., Jin, X., Liang, X. Y. et al., Resveratrol attenuates vascular endothelial inflammation by inducing autophagy through the cAMP signaling pathway. Autophagy 2013, 9, 2033-2045.
15. Colak, Y., Ozturk, O., Senates, E., Tuncer, I. et al., SIRT1 as a potential therapeutic target for treatment of nonalcoholic fatty liver disease. Med. Sci. Monitor 2011, 17, Hy5-Hy9.
16. Pfluger, P. T., Herranz, D., Velasco-Miguel, S., Serrano, M., Tschop, M. H., Sirt1 protects against high-fat diet-induced metabolic damage. Proc. Natl. Acad. Sci. USA 2008, 105, 9793-9798.
17. Deng, X. Q., Chen, L. L., Li, N. X., The expression of SIRT1 in nonalcoholic fatty liver disease induced by high-fat diet in rats. Liver Int. 2007, 27, 708-715.
18. Lee, I. H., Cao, L., Mostoslavsky, R., Lombard, D. B. et al., A role for the NAD-dependent deacetylase Sirt1 in the regulation of autophagy. Proc. Natl. Acad. Sci. USA 2008, 105, 3374-3379.
19. Morselli, E., Maiuri, M. C., Markaki, M., Megalou, E. et al., Caloric restriction and resveratrol promote longevity through the Sirtuin-1-dependent induction of autophagy. Cell Death Dis. 2010, 1, e10.
20. Park, S. J., Ahmad, F., Philp, A., Baar, K. et al., Resveratrol ameliorates aging-related metabolic phenotypes by inhibiting cAMP phosphodiesterases. Cell 2012, 148, 421-433.
21. Sato, F., Martinez, N. E., Shahid, M., Rose, J. W. et al., Resveratrol exacerbates both autoimmune and viral models of multiple sclerosis. Am. J. Pathol. 2013, 183, 1390-1396.
22. Rius, C., Abu-Taha, M., Hermenegildo, C., Piqueras, L. et al., Trans- but not cis-resveratrol impairs angiotensin-II-mediated vascular inflammation through inhibition of NF-kappa B activation and peroxisome proliferator-activated receptor-gamma upregulation. J. Immunol. 2010, 185, 3718-3727.
23. Juan, M. E., Lamuela-Raventos, R. M., de la Torre-Boronat, M. C., Planas, J. M., Determination of trans-resveratrol in plasma by HPLC. Anal. Chem. 1999, 71, 747-750.
24. Sinha, R. A., Farah, B. L., Singh, B. K., Siddique, M. M. et al., Caffeine stimulates hepatic lipid metabolism by the autophagy-lysosomal pathway in mice. Hepatology 2014, 59, 1366-1380.
25. Wang, G. L., Fu, Y. C., Xu, W. C., Feng, Y. Q. et al., Resveratrol inhibits the expression of SREBP1 in cell model of steatosis via Sirt1-FOXO1 signaling pathway. Biochem. Biophys. Res. Commun. 2009, 380, 644-649.
26. Quan, H. Y., Kim, D. Y., Kim, S. J., Jo, H. K. et al., Betulinic acid alleviates non-alcoholic fatty liver by inhibiting SREBP1 activity via the AMPK-mTOR-SREBP signaling pathway. Biochem. Pharmacol. 2013, 85, 1330-1340.
27. Mizushima, N., Yoshimori, T., Levine, B., Methods in mammalian autophagy research. Cell 2010, 140, 313-326.
28. Jeon, T. I., Osborne, T. F., SREBPs: metabolic integrators in physiology and metabolism. Trends Endocrinol. Metab. 2012, 23, 65-72.
29. Shirwany, N. A., Zou, M. H., AMPK in cardiovascular health and disease. Acta Pharmacol. Sin. 2010, 31, 1075-1084.
30. Zechner, R., Madeo, F., Cell biology another way to get rid of fat. Nature 2009, 458, 1118-1119.
31. Singh, R., Kaushik, S., Wang, Y. J., Xiang, Y. Q. et al., Autophagy regulates lipid metabolism. Nature 2009, 458, 1131-U1164.
32. Ford, E. S., Giles, W. H., Dietz, W. H., Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002, 287, 356-359.
33. Sinha, R. A., Farah, B. L., Singh, B. K., Siddique, M. M. et al., Caffeine stimulates hepatic lipid metabolism by the autophagy-lysosomal pathway in mice. Hepatology 2014, 59, 1366-1380.
34. Howitz, K. T., Bitterman, K. J., Cohen, H. Y., Lamming, D. W. et al., Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature 2003, 425, 191-196.
35. Li, L., Hai, J., Li, Z. Q., Peng, H. et al., Resveratrol modulates autophagy and NF-kappa B activity in a murine model for treating non-alcoholic fatty liver disease. Food Chem. Toxicol. 2014, 63, 166-173.
36. Alberdi, G., Rodriguez, V. M., Macarulla, M. T., Miranda, J. et al., Hepatic lipid metabolic pathways modified by resveratrol in rats fed an obesogenic diet. Nutrition 2013, 29, 562-567.
37. Li, Y., Xu, S. Q., Mihaylova, M. M., Zheng, B. et al., AMPK phosphorylates and inhibits SREBP activity to attenuate hepatic steatosis and atherosclerosis in diet-induced insulin-resistant mice. Cell Metab. 2011, 13, 376-388.
38. Baur, J. A., Pearson, K. J., Price, N. L., Jamieson, H. A. et al., Resveratrol improves health and survival of mice on a high-calorie diet. Nature 2006, 444, 337-342.
39. Rivera, L., Moron, R., Zarzuelo, A., Galisteo, M., Long-term resveratrol administration reduces metabolic disturbances and lowers blood pressure in obese Zucker rats. Biochem. Pharmacol. 2009, 77, 1053-1063.
40. Shang, J., Chen, L. L., Xiao, F. X., Sun, H. et al., Resveratrol improves non-alcoholic fatty liver disease by activating AMP-activated protein kinase. Acta Pharmacol. Sin. 2008, 29, 698-706.
41. Pervaiz, S., Holme, A. L., Resveratrol: its biologic targets and functional activity. Antioxid. Redox Signal. 2009, 11, 2851-2897.
42. Tauriainen, E., Luostarinen, M., Martonen, E., Finckenberg, P. et al., Distinct effects of calorie restriction and resveratrol on diet-induced obesity and Fatty liver formation. J. Nutr. Metab. 2011, 2011, 525094.
43. Lee, I. H., Cao, L., Mostoslavsky, R., Lombard, D. B. et al., A role for the NAD-dependent deacetylase Sirt1 in the regulation of autophagy. Proc. Natl. Acad. Sci. USA 2008, 105, 3374-3379.
44. Howitz, K. T., Bitterman, K. J., Cohen, H. Y., Lamming, D. W. et al., Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature 2003, 425, 191-196.
45. Pacholec, M., Bleasdale, J. E., Chrunyk, B., Cunningham, D. et al., SRT1720, SRT2183, SRT1460, and resveratrol are not direct activators of SIRT1. J. Biol. Chem. 2010, 285, 8340-8351.
46. Alers, S., Loffler, A. S., Wesselborg, S., Stork, B., Role of AMPK-mTOR-Ulk1/2 in the regulation of autophagy: cross talk, shortcuts, and feedbacks. Mol. Cell. Biol. 2012, 32, 2-11.
47. Tennen, R. I., Michishita-Kioi, E., Chua, K. F., Finding a target for resveratrol. Cell 2012, 148, 387-389.
48. Franco-Penteado, C., Canalli, A. A., Ferreira, R. P., Saad, S. T. O. et al., cAMP-PKA signaling plays an important role in augmented neutrophil adhesion and chemotaxis in sickle cell disease. Blood 2006, 108, 362a-363a.
49. Yin, W., Mu, J., Birnbaum, M. J., Role of AMP-activated protein kinase in cyclic AMP-dependent lipolysis in 3T3-L1 adipocytes. J. Biol. Chem. 2003, 278, 43074-43080.
50. Collins, S. P., Reoma, J. L., Gamm, D. M., Uhler, M. D., LKB1, a novel serine/threonine protein kinase and potential tumour suppressor, is phosphorylated by cAMP-dependent protein kinase (PKA) and prenylated in vivo. Biochem. J. 2000, 345( Pt 3), 673-680.
51. Gerhart-Hines, Z., Dominy, J. E., Jr., Blattler, S. M., Jedrychowski, M. P. et al., The cAMP/PKA pathway rapidly activates SIRT1 to promote fatty acid oxidation independently of changes in NAD(+). Mol. Cell 2011, 44, 851-863.
52. Francioso, A., Mastromarino, P., Masci, A., d'Erme, M., Mosca, L., Chemistry, stability and bioavailability of resveratrol. Med. Chem. 2014, 10, 237-245.
53. Patel, K. R., Andreadi, C., Britton, R. G., Horner-Glister, E. et al., Sulfate metabolites provide an intracellular pool for resveratrol generation and induce autophagy with senescence. Sci. Transl. Med. 2013, 5, 205ra133.
54. Chachay, V. S., Macdonald, G. A., Martin, J. H., Whitehead, J. P. et al., Resveratrol does not benefit patients with nonalcoholic fatty liver disease. Clin. Gastroenterol. H 2014, 12, U2092-U2383.
55. Faghihzadeh, F., Adibi, P., Rafiei, R., Hekmatdoost, A., Resveratrol supplementation improves inflammatory biomarkers in patients with nonalcoholic fatty liver disease. Nutr. Res. 2014, 34, 837-843.
56. Rojas, C., Valls, C., Pujadas, G., Garcia-Vallve, S., Mulero, M., Chronic treatment with low doses of resveratrol improves non-alcoholic fatty liver disease by modulating endoplasmic reticulum stress related factors. Ann. Nutr. Metab. 2013, 62, 62-62.
57. Xin, P., Han, H., Gao, D. H., Cui, W. et al., Alleviative effects of resveratrol on nonalcoholic fatty liver disease are associated with up regulation of hepatic low density lipoprotein receptor and scavenger receptor class B type I gene expressions in rats. Food Chem. Toxicol. 2013, 52, 12-18.
58. Chen, S., Zhao, X., Ran, L., Wan, J. et al., Resveratrol improves insulin resistance, glucose and lipid metabolism in patients with non-alcoholic fatty liver disease: a randomized controlled trial. Digest. Liver Dis. 2015, 47, 226-232.
59. Heeboll, S., Thomsen, K. L., Pedersen, S. B., Vilstrup, H. et al., Effects of resveratrol in experimental and clinical non-alcoholic fatty liver disease. World J. Hepatol. 2014, 6, 188-198.